Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Am J Cardiol ; 205: 321-324, 2023 10 15.
Artículo en Inglés | MEDLINE | ID: mdl-37633067

RESUMEN

Bempedoic acid is a selective inhibitor of the adenosine triphosphate citrate lyase that reduces low-density lipoprotein cholesterol (LDLc) levels by 17% to 28%. Although the Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (CLEAR-OUTCOMES) trials demonstrated the efficacy on cardiovascular outcomes there is a controversy related to the possible net clinical benefit. Thereafter, we performed an intention-to-treat meta-analysis in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome of the metanalysis was the incidence of major adverse cardiovascular events, defined by each study protocol. Secondary outcomes for the analyses were myocardial infarction, stroke, myocardial revascularization, cardiovascular death, and all-cause death. Results of 4 clinical trials evaluated contained a total of 17,324 patients; 9,236 received bempedoic acid for a median of 46.6 months. The mean baseline LDLc was 129.4 (22.8) mg/100 ml and treatment was associated with a mean LDLc reduction of 26.0 (12.6) mg/100 ml. Treatment with bempedoic acid significantly reduced the incidence of major adverse cardiovascular events (hazard ratio [HR] 0.88, 95% confidence interval [CI] 0.81 to 0.96), myocardial infarction (HR 0.76, 95% CI 0.66 to 0.89) and myocardial revascularization (HR 0.82, 95% CI 0.73 to 0.92); the crude incidence of stroke, cardiovascular or all-cause mortality were lower in patients in the bempedoic acid groups although no significant risk reduction was observed. No heterogeneity was observed in any of the end points. In conclusion, the metanalysis of the 4 clinical trials currently available with bempedoic acid provides reliable evidence of its clinical benefit with no signs of heterogeneity or harm.


Asunto(s)
Infarto del Miocardio , Accidente Cerebrovascular , Humanos , Ensayos Clínicos Controlados Aleatorios como Asunto , Ácidos Dicarboxílicos/uso terapéutico , Ácidos Grasos/uso terapéutico , Infarto del Miocardio/tratamiento farmacológico , Infarto del Miocardio/epidemiología
2.
Magn Reson Imaging ; 86: 149-151, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34813891

RESUMEN

Epicardial Adipose Tissue (EAT) is drawing increasing attention. As a quantifiable, modifiable, and potentially new cardiovascular therapeutic target, its accurate measurement is particularly relevant. In Cardiac Magnetic Resonance (CMR) different methods can be used to assess EAT burden. We take advantage of CMR-studies of EMPATROPISM trial to assess EAT through three different methods, evaluate the effect of Empagliflozin and look for significant difference in the ability to detect changes in serial measurements. In some settings such as treatment-induced changes or patient follow-up, multi-slice method of EAT evaluation provides higher accuracy to detect significant differences, otherwise unnoticed by single-slice approaches.


Asunto(s)
Insuficiencia Cardíaca , Pericardio , Tejido Adiposo/diagnóstico por imagen , Tejido Adiposo/patología , Insuficiencia Cardíaca/patología , Humanos , Imagen por Resonancia Magnética , Pericardio/diagnóstico por imagen
3.
Diabetes Metab Syndr ; 16(2): 102417, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-35121204

RESUMEN

BACKGROUND AND AIMS: Initially considered as just anti-diabetic agents, SGLT2-i show remarkable cardiac and renal benefits independently of its hypoglycemic activity. METHODS: We used the Kansas City Cardiomyopathy Questionnaire (KCCQ), which has recently been qualified as a Clinical Outcome Assessment, in the EMPATROPISM trial. RESULTS: A significant mean improvement of 22 points with KCCQ was seen with Empagliflozin versus only 2 points in the Placebo. The proportion of patients experiencing clinically important changes in the Empagliflozin group was higher. Patients with the lowest starting KCCQ score saw significantly greater improvements. CONCLUSIONS: Empagliflozin benefits quality of life in the non-diabetic, ethnic minority represented, EMPATROPISM trial population.


Asunto(s)
Insuficiencia Cardíaca , Calidad de Vida , Compuestos de Bencidrilo , Etnicidad , Glucósidos , Insuficiencia Cardíaca/tratamiento farmacológico , Humanos , Grupos Minoritarios , Volumen Sistólico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA